Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The ketone body, β-hydroxybutyrate (βOHB), is metabolised by the brain alongside the mandatory brain fuel glucose. To examine the extent and circumstances by which βOHB can supplement glucose metabolism, we studied guinea pig cortical brain slices using increasing concentrations of [U-C]D-βOHB in conjunction with [1-C]D-glucose under conditions of normo- and hypoglycaemia, as well as under high potassium (40 mmol/L K) depolarization in normo- and hypoglycaemic conditions. The contribution of βOHB to synthesis of GABA was also probed by inhibiting the synthesis of glutamine, a GABA precursor, with methionine sulfoximine (MSO). [U-C]D-βOHB at lower concentrations (0.25 and 1.25 mmol/L) stimulated mitochondrial metabolism, producing greater total incorporation of label into glutamate and GABA but did not have a similar effect in the cytosolic compartment where labelling of glutamine was reduced at 1.25 mmol/L [U-C]D-βOHB. At higher concentrations (2.5 mmol/L) [U-C]D-βOHB inhibited metabolism of [1-C]D-glucose, and reduced total label incorporation and total metabolite pools. When glucose levels were reduced, βOHB was able to partially restore the loss of glutamate and GABA caused by hypoglycaemia, but was not able to supplement levels of lactate, glutamine or alanine or to prevent the increase in aspartate. Under depolarizing conditions glucose was the preferred substrate over βOHB, even in hypoglycaemic conditions where comparatively less βOHB was incorporated except into aspartate isotopomers. Inhibition of glutamine synthesis with MSO had no significant effect on incorporation of label from [U-C]D-βOHB into GABA C2,1 indicating that the majority of this GABA was synthesized in GABAergic neurons from [U-C]D-βOHB rather than from Gln C4,5 imported from astrocytes.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11064-017-2228-6DOI Listing

Publication Analysis

Top Keywords

hypoglycaemic conditions
8
incorporation label
8
glutamate gaba
8
βohb
6
[u-c]d-βohb
6
gaba
6
glucose
5
conditions
5
β-hydroxybutyrate boosts
4
boosts mitochondrial
4

Similar Publications

[Tirzepatide (Mounjaro®) : a GIP/GLP-1 receptor dual agonist for the treatment of type 2 diabetes].

Rev Med Liege

September 2025

Service de Diabétologie, Nutrition et Maladies métaboliques, CHU Liège, Belgique.

Tirzepatide is a unimolecular dual agonist of both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, recently commercialized and reimbursed in Belgium for the treatment of type 2 diabetes (T2D). Because of the complementarity of action of the two incretins, tirzepatide showed, in a dose-dependent manner (5, 10 and 15 mg as a once-weekly subcutaneous injection), a better efficacy (greater reduction in HbA1c and body weight) compared with placebo, semaglutide 1 mg, basal insulin and preprandial boluses of insulin lispro in six studies of the SURPASS programme. Tirzepatide tolerance is almost similar to that of pure GLP-1 receptor agonists, with digestive adverse events, most often during the first weeks after initiation, which justifies the recommendation of progressive titration every four weeks.

View Article and Find Full Text PDF

Ultrasound-assisted extraction of naringin from Exocarpium Citri Grandis using a novel ternary natural deep eutectic solvent based on glycerol: Process optimization using ANN-GA, extraction mechanism and biological activity.

Ultrason Sonochem

September 2025

School of Pharmacy, Zunyi Medical University, Zunyi 563000, Guizhou, China; Guizhou Key Laboratory of Modern Traditional Chinese Medicine Creation, Zunyi 563000, Guizhou, China. Electronic address:

This study aimed to develop an efficient green ultrasound-assisted extraction (UAE) method for naringin (Nar) from Exocarpium Citri Grandis (ECG) using a glycerol-based ternary natural deep eutectic solvent (NADES) and explore its biofunctional relevance. After screening and single-factor optimization, the optimal NADES was identified as glycerol:malic acid:propanedioic acid (1:1:2 M ratio, 30 % water content). Extraction conditions (liquid-solid ratio, temperature, time) were optimized via response surface methodology (RSM) and an artificial neural network-genetic algorithm (ANN-GA), with ANN-GA demonstrating superior predictive capability.

View Article and Find Full Text PDF

The treatment of metabolic dysfunction-associated steatotic liver disease involves physical activity, weight loss, and management of comorbidities (diabetes, hypertension, dyslipidemia). In 2024, the American Food and Drug Administration provisionally approved resmetirom for metabolic dysfunction-associated steatohepatitis. Other promising molecules are being evaluated (glucagon-like peptide 1 receptor agonists, fibroblast growth factor 21 agonist).

View Article and Find Full Text PDF

Protection of the Endothelium and Endothelial Glycocalyx by Albumin and Sulodexide in Porcine Model of Kidney Transplant.

Exp Clin Transplant

August 2025

>From the Department of Urology, University Hospital Hradec Kralove, Hradec Kralove, Czechia; and the Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czechia.

Objectives: Kidney transplant is a life-saving procedure for patients with end-stage renal disease. Success of kidney transplant is highly dependent on maintaining the integrity of the endothelium and its protective layer, the endothelial glycocalyx. Ischemia-reperfusion injury, a common challenge in kidney transplant, can disrupt the endothelial glycocalyx, leading to various post-transplant complications.

View Article and Find Full Text PDF

Sodium-glucose cotransporter 2 inhibitors reduced proteinuria in patients with IgA nephropathy; however, their efficacy in patients at high risk of progression receiving immunosuppressive agents and renin angiotensin-aldosterone system inhibitors remains unclear. After 3 months of low-dose steroid alone or combined with mycophenolate mofetil, as well as renin angiotensin-aldosterone system inhibitors treatment, 105 biopsy-proven IgA nephropathy patients with proteinuria greater than 0.5 g/d were included in this study.

View Article and Find Full Text PDF